China SXT Pharmaceuticals, Inc. (SXTC)
NASDAQ: SXTC · Real-Time Price · USD
0.479
-0.051 (-9.64%)
At close: Nov 4, 2024, 4:00 PM
0.488
+0.009 (1.90%)
After-hours: Nov 4, 2024, 7:49 PM EST

Company Description

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China.

The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang.

It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors.

China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

China SXT Pharmaceuticals, Inc.
China SXT Pharmaceuticals logo
Country China
Founded 2005
IPO Date Jan 4, 2019
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 75
CEO Feng Zhou

Contact Details

Address:
178 North Taidong Road
Taizhou, 225300
China
Phone 86 523 8629 8290
Website sxtchina.com

Stock Details

Ticker Symbol SXTC
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency USD
IPO Price $4.00
CIK Code 0001723980
CUSIP Number G2161P108
ISIN Number VGG2161P1403
SIC Code 2834

Key Executives

Name Position
Feng Zhou Chairman of the Board and Chief Executive Officer
Xiaodong Pan Chief Financial Officer
Jun Zheng Executive Director

Latest SEC Filings

Date Type Title
Oct 25, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 22, 2024 F-3 Filing
Oct 15, 2024 6-K Report of foreign issuer
Aug 15, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 13, 2024 20-F Annual and transition report of foreign private issuers
Jul 31, 2024 NT 20-F Notification of inability to timely file Form 20-F
May 31, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
May 14, 2024 6-K Report of foreign issuer
Apr 5, 2024 6-K Report of foreign issuer
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals